skip to Main Content
TreatSMA Are Representing The Community At The NICE Appraisal Of Zolgensma (onasemnogene Abeparvovec-xioi).

TreatSMA are representing the community at the NICE appraisal of Zolgensma (onasemnogene abeparvovec-xioi).

TreatSMA are today representing the community at the NICE appraisal of the first Gene Therapy for SMA, Zolgensma (onasemnogene abeparvovec-xioi).

It is yet another historic day in the history of SMA here in the UK. We hope that NICE will approve Zolgensma and make it available to as many individuals as safely possible.

We will update as soon as we have news.
Back To Top